Federated Hermes Inc. Lowers Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Federated Hermes Inc. lessened its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 98.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,266 shares of the biotechnology company's stock after selling 316,555 shares during the quarter. Federated Hermes Inc.'s holdings in Repligen were worth $758,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Groupama Asset Managment lifted its holdings in Repligen by 12,321.0% in the fourth quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock valued at $58,142,000 after acquiring an additional 400,680 shares during the period. Raymond James Financial Inc. purchased a new stake in Repligen during the fourth quarter worth $52,492,000. Allspring Global Investments Holdings LLC grew its position in Repligen by 79.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after buying an additional 203,011 shares during the period. Alliancebernstein L.P. raised its position in shares of Repligen by 23.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after acquiring an additional 191,439 shares during the period. Finally, Norges Bank purchased a new stake in shares of Repligen during the 4th quarter worth about $24,034,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Trading Up 1.3 %

Shares of Repligen stock traded up $1.64 during mid-day trading on Monday, hitting $131.64. The stock had a trading volume of 678,928 shares, compared to its average volume of 708,183. The firm has a 50-day moving average of $140.09 and a two-hundred day moving average of $145.74. The firm has a market cap of $7.39 billion, a P/E ratio of -258.12, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Sell-side analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

RGEN has been the topic of a number of recent analyst reports. Canaccord Genuity Group lowered their price target on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. Royal Bank of Canada upped their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. JPMorgan Chase & Co. upped their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Finally, StockNews.com lowered Repligen from a "hold" rating to a "sell" rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $176.82.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.